-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 17, Novartis Pharmaceuticals (China) announced that its innovative biological agent Keshan Ting® (Tecuzumab) has been approved by the National Medical Products Administration for the treatment of moderate to severe plaques that meet the indications for systemic therapy or phototherapy.
Psoriasis is an immune-related chronic, recurrent, inflammatory, and systemic disease, with more than 125 million patients worldwide
At present, Coshanting® has been approved for the treatment of psoriasis in children and adults, psoriasis of arthropathy, ankylosing spondylitis, and radiology-negative axial type in many countries and regions including the United States and European Union countries.
In China, Coshanting® has been approved for the treatment of "adult patients with moderate to severe plaque psoriasis who meet the indications of systemic therapy or phototherapy" and "adult patients with ankylosing spondylitis with poor conventional therapy" Patients", and will be officially included in the National Medical Insurance Directory in 2020